La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Tourmaline Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Tourmaline Bio..

Tourmaline Bio (NASDAQ:TRML) Azioni, Catena delle Opzioni

TOURMALINE BIO INC

Tourmaline Bio

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

<ul>
<li>The combined company plans to launch ZELSUVMI&#x2122; for the treatment of molluscum contagiosum infections in July 2025</li>
<li>Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement</li>
<li>Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025</li>
</ul>

News

CHRO

Pelthos Therapeutics Completes Merger With Channel Therapeutics, Closes $50.1M Private Placement, And Prepares For July 2025 ZELSUVMI Launch

Shattuck Labs, Inc. (Shattuck) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will participate in a DR3/TL1A focused panel discussion and participate in one-on-one meetings at the Leerink Partners Therapeutics Forum: I&amp;I and Metabolism on July 8–9, 2025 in Boston, MA.

STTK

Shattuck Labs Management To Participate In DR3/TL1A Focused Panel Discussion And In One-On-One Meetings At Leerink Partners Therapeutics Forum: I&I And Metabolism

Diversified Energy Promotes Michael Garrett To Chief Accounting Officer, Tapping 20-Year Industry Veteran To Lead Financial Reporting Teams

Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>), today announced that it has formed a best-in-class clinical and translational study group, the SPEAR Study Group, with leading investigators focused on the biology and clinical disease or injury associated with chronic exposure to SARS-CoV-2 virus or mRNA vaccine-mediated spike protein. The SPEAR Study Group will structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in people suffering from Long COVID or Post-Vaccination Syndrome (PVS), conditions believed to be mediated by persistent viral reservoirs or circulating spike protein. Persistent SARS-CoV-2 spike protein has been identified in both populations, and both populations have overlapping manifestations of apparent clinical disease. As many as 5% or more of Americans have reported recent Long COVID symptoms, an extraordinary medical burden that will continue to evolve as infections continue in the U.S. The SPEAR Study Group was initiated in response to a growing number of case reports and reported case series from across the U.S. suggesting meaningful symptom relief / remission of Long COVID following use of PEMGARDA&#xAE; (pemivibart), a monoclonal antibody currently authorized by the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals. PEMGARDA is not authorized for the treatment of Long COVID. While these emerging reports are anecdotal and uncontrolled, they collectively support a longstanding, mechanistically plausible hypothesis: that prolonged exposure to pathogenic SARS-CoV-2 spike protein or other forms of persistent virus or viral material may drive disease in some patients, and that reducing this burden through monoclonal antibody therapy may offer a promising therapeutic approach worthy of rigorous clinical investigation. Clinical research to be planned by the SPEAR Study Group is critical to exploring disease biology and evaluating efficacy endpoints that can enable registrational studies if appropriate in the future.
The SPEAR Study Group includes the following investigators and researchers who, along with Invivyd, will collaborate on the design and anticipated execution of relevant clinical trials:
<ul>
<li>Michael Peluso, M.D., MHS, Assistant Professor of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco</li>
<li>Amy Proal, Ph.D., Co-Founder and CEO, Polybio Research Foundation and Scientific Director, Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ("CoRE")</li>
<li>David Putrino, Ph.D., Nash Family Director of the Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ("CoRE") and Professor, Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai. &nbsp;</li>
</ul>
The SPEAR Study Group intends to launch collaborative, multi-center translational clinical research on Long COVID, including PVS, as soon as practicable, including use of next-generation monoclonal antibody candidates from Invivyd such as VYD2311.

IVVD

Invivyd Launches SPEAR Study Group to Explore Monoclonal Antibody Treatment for Long COVID and Post-Vaccine Syndrome

CTSO

CytoSorbents Pursues Supervisory Review With US FDA And Reconsideration With Health Canada For DrugSorb-ATR Marketing Applications

TNXP

Tonix Publishes Preclinical Data In Cancer Cell Showing mTNX-1700 Plus Anti-PD1 Boosts Survival, Cuts Metastases In Gastric Cancer Models

<a href="https://www.globenewswire.com/Tracker?data=B_vGmX7fTbv_YwYYV_7hIU065_i16wOLd0WJjgzRKav23q7vjszeCaYYqPPHB5pn5ytZ2F-PhlWj_p6S37JzvA==">Dayforce</a>, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/DAY#TSX">DAY</a>), a global human capital management (HCM) leader that makes work life better, today announced the rebranding of its payroll and HR solution for Canadian small and mid-sized businesses (SMBs) as Powerpay by Dayforce, signaling a renewed strategic focus and ongoing commitment to meeting the unique and evolving needs of its more than 46,000 customers across Canada.
SMBs drive Canada's economy, contributing billions to its GDP each year and <a href="https://www.globenewswire.com/Tracker?data=iiCSoYm4seoHAQZsCmi1XUe8N68667QEoiNZm-ADAieAlLdvGB33qS4Im5zYripM1BrvuLhi5az_32RIbaHopnU_ZyfWBU7rwMg15N_b1ylNDnjkIyn-czhaFsV5scLshlw6H0aJbP8WKzMG-PeUuzYHP2Gtw41VIigjkwtd5OBmgfaLuXM9l_LUtyz5dIuxwXIoOWopI588w01gmbuIF-zJrnKtk2TEV91tUz8xP0ZwsuEdOmDvLmhwhCWL_ZpE">representing nearly the entire business landscape</a>. But running one has never been more complex. With hundreds of legislative changes introduced annually, business owners face a fast-changing landscape of compliance and employment regulations. To stay focused on growth, they need simple, reliable tools that help pay their people accurately and compliantly.

TSX:DAY

Dayforce Rebrands Canadian SMB Payroll Platform as Powerpay to Better Serve 46,000+ Customers

<a href="https://www.globenewswire.com/Tracker?data=81PCLcHSVz_3cmFZGpaG7F4aVM20ywRSuPRmoYtSkNjLEDZr00O7xvPYTgCirP-qMrO1NDc3GV1CN1TzVE420Wp50sX8yROYt3V0YGQlLHE=">Cipher Mining Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) ("Cipher" or the "Company") today announced that Phase I of Black Pearl is now delivering ~3.4 EH/s of self-mining capacity, exceeding the Company's prior guidance of 2.5 EH/s for the second quarter of 2025. Hashrate will continue to increase at the site through the third quarter of 2025 as new mining rigs continue to be delivered in scheduled batches, gradually replacing legacy units. Cipher's total self-mining hashrate has now reached ~16.8 EH/s, and the Company maintains its expectations to scale to ~23.1 EH/s upon completion of the installation.

CIFR

CIFRW

Cipher Mining Says Phase I Of Black Pearl Is Now Delivering ~3.4 EH/S Of Self-Mining Capacity, Exceeding Prior Guidance Of 2.5 EH/S For Q2 2025

Alta Equipment Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) ("Alta" or "the Company"), a leading provider of premium material handling, construction and environmental processing equipment and related services, today announced that its Board of Directors approved the quarterly dividend on its Series A Cumulative Perpetual Preferred Stock in the amount of $625 per preferred share. This will equate to a dividend of $0.625 for each of the outstanding Depositary Shares representing a 1/1000th fractional interest in one share of Series A Preferred. The dividend payment date is July 31, 2025, to shareholders of record at the close of business on July 15, 2025.

Dividends

ALTG

Alta Equipment Declares $0.625 Dividend on Preferred Stock, Payable July 31

Tech bull Daniel Ives has urged Tim Cook&#8216;s Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to make quick moves and acquire Perplexity AI for its search engine.
What Happened: Stating that Apple was kind of a &#8220;yawner&#8221; at the <a href="https://www.benzinga.com/markets/tech/25/06/45846510/apple-wwdc-2025-from-live-translation-to-genmoji-visual-ai-and-chatgpt-integration-here-are-the-new-apple-intelligence-features">WWDC 2025</a> event, Dan Ives said the iPhone maker needs to &#8220;make a move,&#8221; in an interview with <a href="https://www.cnbc.com/video/2025/07/01/dan-ives-techs-huge-rally-will-continue-in-the-second-half-of-the-year.html">CNBC</a> during its &#8216;Power Lunch&#8217; program. 
He said that Apple&#8217;s &#8220;treadmill approach&#8221; needs to end, and it needs to eye a big splashing partnership with either&nbsp;Perplexity or Anthropic.
While Ives has previously mentioned that he expects <a href="https://www.benzinga.com/markets/equities/25/06/45899111/apple-may-end-up-acquiring-perplexity-like-it-did-with-beats-in-2014-says-dan-ives-consumers-need-reasons-to-upgrade-as-iphone-maker-falls-way-behind-in-ai-race">Apple to consider acquiring Perplexity</a>, he said in this latest conversation that &#8220;It&#8217;s a matter of when and not if, in other words, Apple needs to make a move, and it&#8217;s clear. Perplexity to me seems like a no-brainer, relative to how it would fit.&#8221; 
&#8220;Look, it&#8217;s about the developers. If you look at OpenAI, if you look at Google, if you look at Microsoft, they (Apple) need to get into the game. That is something that can&#8217;t be done in Cupertino,&#8221; he added.
He also reiterated his belief in positive upward momentum in Apple&#8217;s stock by saying that &#8220;The reason the stock can go up in the second half of the year is that I think Apple is going to make a move. I know they still haven&#8217;t done an acquisition since Beats, being the biggest one, but now is the time for Cook and Cupertino to move away from the treadmill approach.&#8221;
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45880840/jim-cramer-says-apple-buyback-is-not-working-right-now-michael-saylor-quips-tim-cooks-company-should-buy-bitcoin">Jim Cramer Says &#8216;Apple Buyback Is Not Working Right Now,&#8217; Michael Saylor Quips Tim Cook&#8217;s Company &#8216;Should Buy Bitcoin&#8217;</a>
Why It Matters: In an X post from June 10, Jim Cramer also advocated for more <a href="https://www.benzinga.com/markets/equities/25/06/45880840/jim-cramer-says-apple-buyback-is-not-working-right-now-michael-saylor-quips-tim-cooks-company-should-">ambitious capital allocation</a> strategies for Apple.
"I have to be critical and say they should buy Perplexity," he stated.
His advice is driven by the expected U.S. government <a href="https://www.benzinga.com/news/topics/25/05/45708275/googles-monopoly-case-takes-a-turn-as-judge-considers-lighter-remedies-amid-rising-competition-from-ai-rivals-like-openai-and-perplexity">antitrust decision against</a> Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google by August 2025, which could disrupt Google's default search agreements with Apple's Safari browser.
Such a change would enable Apple to adopt Perplexity's conversational AI to enhance its competitiveness in the rapidly changing search market, Cramer explained.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I know Apple has an aversion to wanting to buy anything, i have to be critical and say they should buy Perplexity. I know they can wait until someone pays them to be their default a.i. but that&#39;s what Google did with search and the US government didn&#39;t like it, so move on and buy
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1932377641442496542?ref_src=twsrc%5Etfw">June 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: Shares of Apple were up 0.76% in premarket on Wednesday after ending 1.29% higher on Tuesday. It fell by 14.78% on a year-to-date basis and 5.65% over the past year.
Benzinga Edge Stock Rankings shows that Apple had a weaker price trend over the medium and long term but a stronger trend over the short term. Its momentum ranking was poor, and its value ranking was also bad at the 9.05th percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="156" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02061241/Apple-edge-latest-1024x156.png" alt="" class="wp-image-970106" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02061241/Apple-edge-latest-1024x156.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02061241/Apple-edge-latest-300x46.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02061241/Apple-edge-latest-768x117.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02061241/Apple-edge-latest.png 1159w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, edged slightly higher on Wednesday. The SPY was up 0.097% at $618.25, while the QQQ advanced 0.05% to $547.27, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46213361/trump-is-slamming-jerome-powell-because-he-wants-a-weaker-dollar-says-ed-yardeni-pounding-powell-po" target="_blank" rel="noreferrer noopener">Trump Is Slamming Jerome Powell Because He ‘Wants A Weaker Dollar,' Says Ed Yardeni: ‘Pounding Powell = Pounding The Dollar'</a></li>
</ul>
Photo: Shutterstock

AAPL

GOOG

GOOGL

Dan Ives Urges Apple 'To Make A Move,' Saying That Perplexity Acquisition Is 'A No-Brainer': 'It's A Matter Of When And Not If'

Assurant Expands Partnership With Dr. Phone Fix To Accelerate Certified Pre-Owned Phone Sales Across Canada

AMC Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) (the "Company") announced the early results, as of 5:00 p.m. New York City time, on July 1, 2025 (the "Early Tender Date") of its previously announced cash tender offer (the "Offer") to purchase its outstanding 4.25% Senior Notes due 2029 (the "Notes") and that it has amended the Offer by increasing the maximum aggregate principal amount of Notes it may purchase in the Offer from $450,000,000 to $600,000,000 (the "Maximum Tender Amount").
The terms and conditions of the Offer are described in an Offer to Purchase, dated June 17, 2025 (as amended and supplemented by this news release, the "Offer to Purchase"), which was previously distributed to holders of the Notes. As set forth in the Offer to Purchase, the Company reserves the right to (i) waive any and all conditions to the Offer as permitted by law, (ii) extend or terminate the Offer or (iii) otherwise amend the Offer.

AMCX

AMC Networks Ups Tender Offer to $600M (Up From Prior $450M) for 2029 Notes After Strong Early Interest

Companies to Commercialize Integrated Solution for DPP Deployments Ahead of Forthcoming European Union Regulations
SANTA ANA, Calif., July 2, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4461105-1&amp;h=2868137247&amp;u=https%3A%2F%2Fidentiv.com%2F&amp;a=Identiv%2C+Inc">Identiv, Inc</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4461105-1&amp;h=2505524645&amp;u=https%3A%2F%2Fidentiv.com%2F&amp;a=.">.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>), a global leader in RFID- and BLE-enabled Internet of Things (IoT) solutions,&nbsp;announced today that it has entered into a partnership with Narravero GmbH.,&nbsp;a global Software-as-a-Service (SaaS) platform for Digital Product Passports (DPPs) and supply chain transparency. This collaboration expects to accelerate the commercialization of integrated solutions for EU-compliant DPP deployments. By combining Identiv's NFC inlays for dynamic product data with Narravero's robust data management platform, this partnership offers a comprehensive, integrated solution that streamlines DPP deployment for companies.

INVE

Identiv Partners With Narravero To Accelerate Commercialization Of Integrated Solutions For EU-Compliant DPP Deployments

SRDX

Surmodics Reports Unauthorized IT Access, Initiates Containment Measures Following Cybersecurity Incident

GLGI

Greystone Logistics Completes 1M Share Buyback Program, Signals Potential Expansion To Boost Shareholder Value

Main Street Capital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAIN#NYSE">MAIN</a>) ("Main Street") is pleased to announce that it recently completed a follow-on portfolio investment to facilitate the minority recapitalization of its existing portfolio company, Flame King Holdings, LLC ("Flame King" or the "Company"), a leading supplier of propane storage solutions and accessories. Main Street funded $66.0 million of first-lien, senior secured term debt to complete the recapitalization and also provided Flame King with a revolving line of credit to support the Company's ongoing growth initiatives and working capital needs. Main Street initially invested in Flame King in October 2021.

MAIN

Main Street Capital Invests $66M to Back Flame King's Recapitalization and Growth Plans

ASTH

Astrana Updates 2025 Guidance After Prospect Health Deal; Sees $3.1B–$3.3B Revenue, $215M–$225M EBITDA, Targets $12M–$15M Synergies

<ul>
<li>Term Loan Lenders representing more than 80% of AMC's term loans outstanding under its Credit Agreement already have consented to allow for the beneficial transactions announced on July 1, 2025 to proceed</li>
<li>Additional Term Loan Lenders who also wish to provide their consent still can do so through 5:00 pm EDT todaY</li>
</ul>

AMC Entertainment Secures Requisite Term Loan Lender Consents For Balance Sheet Strengthening Transactions

Pursuit Attractions and Hospitality, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRSU#NYSE">PRSU</a>) ("Pursuit") today announced the acquisition of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tabacon.com%2F&amp;esheet=54285072&amp;newsitemid=20250702557150&amp;lan=en-US&amp;anchor=Tabac%26oacute%3Bn+Thermal+Resort+%26amp%3B+Spa&amp;index=1&amp;md5=4cb8725342258450acfbc9099e91f6da">Tabacón Thermal Resort &amp; Spa</a> ("Tabacón"), a renowned luxury retreat in the Arenal region of Costa Rica. This transaction marks a significant step in Pursuit's global growth strategy, expanding its signature hospitality experiences into another one of the world's most iconic travel destin

PRSU

Pursuit Expands Globally With Acquisition of Luxury Tabacón Resort in Costa Rica

The London-based design disruptor teams up with Ceva to power enhanced listening experiences across the Nothing and CMF sub-brand audio product lines, including the newly announced Nothing Headphone (1)
LONDON and ROCKVILLE, Md., July 2, 2025 /PRNewswire/ -- In a move that pushes the boundaries of personal audio, Ceva, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>), the leading licensor of silicon and software IP for the Smart Edge, and Nothing, the London-based consumer technology company known for its&nbsp;transparent, design-forward smartphones, audio products and wearables that blend style with performance, today announced a new collaboration to bring Ceva's RealSpace&#xAE; <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4460196-1&amp;h=1785984280&amp;u=https%3A%2F%2Fwww.ceva-ip.com%2Fproduct%2Fceva-realspace%2F%3Futm_source%3DPR%26utm_medium%3Demail%26utm_campaign%3DNothing-PR&amp;a=Spatial+Audio">Spatial Audio</a> Software to Nothing's upcoming audio lineup, including the newly announced <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4460196-1&amp;h=4111100270&amp;u=https%3A%2F%2Fnothing.tech%2Fproducts%2Fheadphone-1&amp;a=Nothing+Headphone+(1)">Nothing Headphone (1)</a>, which is the company's highly anticipated first entry into the over-ear style audio device.

CEVA

Ceva And Nothing Collaborate To Bring Ceva's RealSpace Spatial Audio Software To Nothing's Upcoming Audio Lineup

Earnings

Press Releases

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

Management

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

Comments

Tourmaline Bio

Tourmaline Bio (TRML) Opzioni

Tourmaline Bio (NASDAQ:TRML) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO